文献速递脊柱外科

腰椎融合术后阿片类药物使用:趋势及与长期使用相关的因素

Opioid Utilization Following Lumbar Arthrodesis: Trends and Factors Associated With Long-term Use.
PubMed 文献 · Spine (Phila Pa 1976) · 2018-01-01

这项回顾性观察性队列研究利用2007至2015年全国商业理赔数据集,分析26553例腰椎融合术患者围手术期阿片类药物使用趋势。术前慢性阿片类药物使用者占58.3%,术后1年阿片类药物处方填充率在使用者中为42.4%、在未使用者中为8.6%(P<0.001)。术前阿片类药物使用是术后1年麻醉药品使用的最强驱动因素。

要点

  • 腰椎融合术前慢性阿片类药物使用者占58.3%,术后1年仍有42.4%继续填充阿片类药物处方。
  • 术前阿片类药物使用是ALIF术后1年麻醉药品使用最强驱动因素(OR 7.86,P<0.001)。
  • 术后3个月阿片类药物处方率在未使用者中降至13.9%,在使用者中降至53.8%。

核心结论

  • 约三分之一患者在腰椎融合术前长期使用阿片类药物,近半数术前阿片类药物使用者在术后1年仍继续使用。
  • 研究结果可作为识别慢性使用风险患者的基线,并促使外科医生在腰椎手术前努力停用阿片类药物。

研究设计与样本

  • 回顾性观察性队列研究,查询2007至2015年全国商业理赔数据集,纳入所有接受前路腰椎椎间融合术和/或腰椎后路/经椎间孔腰椎椎间融合术或后外侧融合术的患者。
  • 共26553例患者接受腰椎手术,其中前路腰椎椎间融合术占8.5%、后路/经椎间孔腰椎椎间融合术占43.8%、后外侧融合术占41.5%、前路腰椎椎间融合术+后外侧融合术占6.2%。
  • 患者分为阿片类药物使用者(术前3个月内有处方)和阿片类药物未使用者(无处方),纵向追踪至术后1年,采用多变量回归分析术后1年阿片类药物使用的相关因素,并创建临床计算器(应用程序)预测1年麻醉药品使用。

主要发现

  • 术后1个月,阿片类药物未使用者中60.2%、使用者中82.9%有阿片类药物处方填充。
  • 术后3个月,处方率显著下降至未使用者13.9% vs 使用者53.8%,术后6至12个月趋于平台(未使用者8.4-9.6%;使用者42.1-45.3%)。
  • 术后1年,阿片类药物使用者麻醉药品处方填充率显著高于未使用者(42.4% vs 8.6%;P<0.001)。
  • 术前阿片类药物使用是前路腰椎椎间融合术后1年麻醉药品使用的最强驱动因素(OR 7.86;P<0.001)、后路/经椎间孔腰椎椎间融合术(OR 4.62;P<0.001)或后外侧融合术(OR 7.18;P<0.001)。

临床怎么用

  • 作者认为研究结果可作为识别慢性使用风险患者的基线,并促使外科医生在腰椎手术前努力停用阿片类药物。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

STUDY DESIGN: A retrospective, observational cohort study. OBJECTIVE: In patients undergoing lumbar spine arthrodesis, we sought to establish perioperative trends in chronic versus naive opioid users (OUs) and identify modifiable risk factors associated with prolonged consumption. SUMMARY OF BACKGROUND DATA: The morbidity associated with excessive opioid use for chronic conditions continues to climb and has been identified as a national epidemic. Limiting excessive perioperative opioid use after procedures such as lumbar fusion remains a national health strategy. METHODS: A national commercial claims dataset (2007-2015) was queried for all patients undergoing anterior lumbar interbody fusion (ALIF) and/or lumbar [posterior/transforaminal lumbar interbody fusion (P/TLIF) or posterolateral fusion (PLF)] spinal fusion procedures. Patients were labeled as either an OU (prescription within 3 months pre-surgery) or opioid naive (ON, no prescription). Rates of opioid use were evaluated preoperatively for OU, and longitudinally tracked up to 1-year postoperatively for both OU and ON. Multivariable regression techniques investigated factors associated with opioid use at 1-year following surgery. In addition, a clinical calculator (app) was created to predict 1-year narcotic use. RESULTS: Overall, 26,553 patients (OU: 58.3%) underwent lumbar surgery (ALIF: 8.5%; P/TLIF: 43.8%; PLF: 41.5%; ALIF+PLF: 6.2%). At 1-month postop, 60.2% ON and 82.9% OUs had a filled opioid prescription. At 3 months, prescription rates declined significantly to 13.9% in ON versus 53.8% in OUs, while plateauing at 6 to 12-month postoperative period (ON: 8.4-9.6%; OU: 42.1-45.3%). At 1 year, significantly higher narcotic prescription filling rates were observed in OUs than in ON (42.4% vs. 8.6%; P < 0.001). Preoperative opioid use was the strongest driver of 1-year narcotic use following ALIF [odds ratio (OR): 7.86; P < 0.001], P/TLIFs (OR: 4.62; P < 0.001), or PLF (OR: 7.18; P < 0.001). CONCLUSION: Approximately one-third patients chronically use opioids before lumbar arthrodesis and nearly half of the pre-op OUs will continue to use at 1 year. Our findings serve as a baseline in identifying patients at risk for chronic use and alter surgeons to work toward discontinuation of opioids before lumbar spinal surgery. LEVEL OF EVIDENCE: 3.

来源:Spine (Phila Pa 1976),查看原文。版权归原作者所有。

引用

  1. Kalakoti P, Hendrickson NR, Bedard NA, et al. Opioid Utilization Following Lumbar Arthrodesis: Trends and Factors Associated With Long-term Use. Spine (Phila Pa 1976). 2018. PMID: 30045343. doi:10.1097/BRS.0000000000002734

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。